ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,505.00
      -0.71%
      US Tech 100
      19,005.20
      -0.91%
      Dow Jones
      40,287.53
      -0.93%
      Brent Oil
      81.875
      0.00%
      Bitcoin
      66,648.55
      -0.10%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Longboard Pharmaceuticals Inc (LBPH) Quote

      Longboard Pharmaceuticals Inc

      Longboard Pharmaceuticals Inc (LBPH)

      NASDAQ
      35.95
      -0.05
      (-0.14%)
      Closed July 19 4:00PM
      Delayed by 15 minutes
      35.95
      0.07
      (0.20%)
      After Hours: 5:30PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      35.95
      Bid
      31.01
      Ask
      39.60
      Volume
      607,867
      35.54 Day's Range 37.21
      3.60 52 Week Range 40.48
      Market Cap
      1.4B
      Previous Close
      36.00
      Open
      35.90
      Last Trade
      1
      @
      35.99
      Last Trade Time
      Financial Volume
      $ 22,015,775
      VWAP
      36.2181
      Average Volume (3m)
      503,614
      Shares Outstanding
      38,880,054
      Dividend Yield
      -
      PE Ratio
      -25.63
      Earnings Per Share (EPS)
      -1.4
      Revenue
      -
      Net Profit
      -54.42M

      About Longboard Pharmaceuticals Inc

      Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659. Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.longboardpharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Longboard Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LBPH. The last closing price for Longboard Pharmaceuticals was $36. Over the last year, Longboard Pharmaceuticals shares have traded in a share price range of $ 3.60 to $ 40.48.

      Longboard Pharmaceuticals currently has 38,880,054 shares outstanding. The market capitalization of Longboard Pharmaceuticals is $1.40 billion. Longboard Pharmaceuticals has a price to earnings ratio (PE ratio) of -25.63.

      LBPH Latest News

      More News

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      July 03 2024
      Business Wire

      Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

      U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies...

      July 01 2024
      Business Wire

      Form 8-K - Current report

      June 10 2024
      Edgar (US Regulatory)

      Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

      Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group...

      June 10 2024
      Business Wire

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      June 03 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      May 24 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 24 2024
      Edgar (US Regulatory)

      Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

      May 06 2024
      Business Wire

      Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

      Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data...

      May 02 2024
      Business Wire

      Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

      PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the...

      April 03 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-2.95-7.5835475578438.940.39535.0571511737.4927397CS
      415.979.301745635920.0540.4819.659795898231.037049CS
      1216.786.753246753219.2540.4815.6450361426.94367614CS
      2611.9549.79166666672440.4815.6454737723.40389104CS
      5228.75399.3055555567.240.483.655074922.91460908CS
      15627.3315.6069364168.6540.482.720963920.91640914CS
      26019.95124.68751640.482.719472520.58507357CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		266.23M
      AUGXAugmedix Inc
      $ 2.27
      (147.71%)
      		24.14M
      XCURExicure Inc
      $ 0.5351
      (76.02%)
      		14.02M
      PSNLPersonalis Inc
      $ 3.83
      (56.33%)
      		22.8M
      MDBHMDB Capital Holdings LLC
      $ 10.675
      (37.21%)
      		126.45k
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		124.61M
      HYZNHyzon Motors Inc
      $ 0.149
      (-47.54%)
      		23.63M
      MEDSTRxADE Health Inc
      $ 14.92
      (-33.45%)
      		223.27k
      SILOSilo Pharma Inc
      $ 2.50
      (-27.95%)
      		11.93M
      KITTNauticus Robotics Inc
      $ 0.0935
      (-27.46%)
      		28.36M
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		266.23M
      SXTP60 Degrees Pharmaceuticals Inc
      $ 0.2602
      (5.77%)
      		226.79M
      NVDANVIDIA Corporation
      $ 117.93
      (-2.61%)
      		217.1M
      SQQQProShares UltraPro Short QQQ
      $ 8.46
      (2.79%)
      		188.2M
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		124.61M

      LBPH Discussion

      View Posts
      TechandBio TechandBio 1 week ago
      MY best performing Bio this year! Surfs up Vertical debit spreads from $5.00 are up over 1430% wish i went heavier keep an eye on ICCM

      $LBPH
      👍️0
      da_stock_analyst da_stock_analyst 6 months ago
      #LBPH 🔥 short squeeze might push this way higher! Nice set up!
      👍️0
      Backstabbed Backstabbed 7 months ago
      Insane … grats all
      👍️0
      conix conix 7 months ago
      LOTTO Ticket for 2024: Curative Biotechnology $CUBT @ $0.02 is a biotech with some very promising technology in the treatment of Age-Related Macular Degeneration (AMD). Metformin, a widely used diabetes drug, has been proven to have positive effects on patients with AMD. CUBT has a patented formulation for the direct delivery of metformin to the eye in the form of eye drops. The National Institutes of Health (NIH) will be funding a clinical trial on humans in 2024 in collaboration with the company. There has been a number of delays in the start of the trials, hence the low price, but the price has been firming up this past month. Although difficult to predict when these announcements happen, at these prices, CUBT is worth buying a small position (you can define "small") to make certain you are following the news and the price reaction so you can average up on your original position. Check the CUBT website out to see more info on the trials and the company's other drugs in the pipeline. Target Price by end of First Quarter (assuming clinical trial announcement)--$0.15).

      SOURCE: https://www.reddit.com/r/pennystocks/comments/18uvm1j/trading_ideas_for_january_sing_migi_cubtmentioned/

      It should go without saying, BUT some may need to read it...the above is someone's opinion. Nice to see anyways.
      👍️0
      conix conix 7 months ago
      Congrats on being a quick thinker. Per-market buying can be risky, but does pan out.
      👍️0
      TheFinalCD TheFinalCD 7 months ago
      The company has 9.5 months of cash left based on quarterly cash burn of -$13.28M and estimated current cash of $42.0M.
      https://dilutiontracker.com/app/search/LBPH?a=dbb88c
      👍️0
      Stockexpertpro Stockexpertpro 7 months ago
      AVTX Data Due on Watch here after 1 for 240 RS micro Float
      👍️0
      Laster Laster 7 months ago
      Grabbed some at 8am immediately following news.
      Looking good moving into open.
      Sold half on double. Riding rest free.
      What a way to start 2024!
      👍️0
      Monksdream Monksdream 7 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      tw0122 tw0122 7 months ago
      An epileptic profit nice…
      👍️0
      cityimport cityimport 7 months ago
      My First Almost 200% Profit (Within One Hour) In 2024 ... :)))))))))))))

      In @ 6.25
      Out @ 17.95

      LBPH
      👍️0

      Your Recent History

      NASDAQ
      LBPH
      Longboard Pharmaceuticals
      Delayed Upgrade Clock